Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Dr Reddy's Laboratories Ltd (RDDA.SG)

Compare

12.40

-0.10

(-0.80%)

At close: February 27 at 3:58:19 PM GMT+1

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

HYDERABAD, India, February 06, 2025--Dr. Reddy’s Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.

Business Wire 21 days ago

2696.HK

RDY
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclus

PR Newswire 21 days ago

RDY

2696.HK
Dr. Reddy’s Q3 & 9MFY25 Financial Results

HYDERABAD, India, January 23, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.

Business Wire last month

RDY
Dr. Reddy’s Laboratories Allocates Equity Shares to Employees

Dr Reddy’s Laboratories ( (RDY) ) has provided an update. Dr. Reddy’s Laboratories has approved the allotment of 13,080 equity shares to employees under its Employees Stock Options Scheme, 2002, as part of its commitment to rewarding and retaining talent. This move reflects the company’s strategic approach to employee compensation and its continuous efforts to align employee interests with its business objectives, potentially enhancing stakeholder value. More about Dr Reddy’s Laboratories Dr. Re

TipRanks 2 months ago

RDY
Dr. Reddy’s Boosts Workforce with Equity Allotment

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has announced the allotment of 26,150 equity shares to employees who exercised their stock options under the company’s 2002 Employee Stock Options Scheme. This move reflects the company’s ongoing commitment to rewarding its workforce and could potentially influence investor sentiment positively. As these shares are fully paid and identical to existing shares, it ensures seamless integration into the current market str

TipRanks 2 months ago

RDY
Dr. Reddy’s Launches Innovative Cancer Drug in India

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has launched Toripalimab in India, marking it as the first immuno-oncology drug approved for nasopharyngeal carcinoma (NPC) in the country. This launch positions India as the third nation globally to access this innovative treatment, following China and the U.S. Toripalimab has demonstrated a 48% reduction in disease progression risk when combined with standard chemotherapy, addressing a significant need for advanced

TipRanks 2 months ago

RDY
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

HYDERABAD, India, November 28, 2024--Dr. Reddy’s Laboratories Ltd. announced the launch of Toripalimab in India.

Business Wire 2 months ago

RDY
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India, November 26, 2024--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.

Business Wire 3 months ago

RDY
Dr. Reddy’s Gains Strong Rating Amid Robust Growth

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has received an ‘IND AA+/Stable’ rating from India Ratings & Research for its bank facilities, reflecting a solid financial position and continued growth in the US generic market. The company’s robust performance is driven by a diverse product mix, strategic launches, and improved operating efficiencies, despite challenges such as regulatory concerns and divestment impacts in India. Investors may find Dr. Reddy’s stro

TipRanks 3 months ago

RDY
Dr. Reddy’s Q2 & H1FY25 Financial Results

HYDERABAD, India, November 05, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.

Business Wire 3 months ago

RDY
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

HYDERABAD, India, October 25, 2024--Dr. Reddy’s has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science.

Business Wire 4 months ago

RDY
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

PRINCETON, N.J., October 14, 2024--Dr. Reddy’s launches comprehensive menopause support program and training for employees during menopause awareness month.

Business Wire 4 months ago

RDY
Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical response rate without any high-grade safety concerns, paving the way for the Phase 2 trial with regulatory approval. These findings could mark a significant advancement in treatment options for Indian myeloma patients. For

TipRanks 4 months ago

RDY
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

BENGALURU, India & HYDERABAD, India, October 08, 2024--Aurigene Oncology announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma.

Business Wire 4 months ago

RDY
Dr. Reddy’s Unveils New Danish Subsidiary

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has expanded its global footprint by establishing a new wholly-owned subsidiary, Dr. Reddy’s Denmark ApS, in Denmark. This strategic move, aligning with the company’s main pharmaceutical and biotechnological business, involves the subsidiary promoting production and related activities in Denmark. The cash-funded acquisition makes Dr. Reddy’s Denmark ApS a step-down subsidiary of the parent company. For further insight

TipRanks 4 months ago

RDY
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

HYDERABAD, India, October 02, 2024--Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.

Business Wire 4 months ago

RDY
Dr. Reddy’s Acquires Global NRT Leader Nicotinell

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories Ltd. has completed the acquisition of Haleon plc’s Nicotinell brand and related NRT products, expanding its consumer healthcare portfolio. The deal, valued at GBP 458 million, brings Nicotinell and other local market-leading NRT brands into Dr. Reddy’s fold, enhancing its global OTC business presence. This strategic move aligns with the company’s growth in consumer healthcare, complementing recent ventures such as the

TipRanks 4 months ago

RDY
Dr. Reddy’s Expands Portfolio with $620M Investment

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm’s length, aims to bolster the company’s pharmaceutical portfolio and strengthen its market position. The investment involved the allotment of 6.2 million non-convertible preference shares to the parent company. For f

TipRanks 4 months ago

RDY
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

HYDERABAD, India, August 20, 2024--Dr. Reddy’s Laboratories, Aurigene, and Kainomyx announce potential partnership for joint development of affordable anti-malarial drug.

Business Wire 6 months ago

RDY
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

HYDERABAD, India, July 29, 2024--Dr. Reddy’s receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar.

Business Wire 6 months ago

RDY

Performance Overview

Return	RDDA.SG	S&P BSE SENSEX
YTD	-16.78%	-5.73%
1-Year	-11.05%	+1.88%
3-Year	+43.08%	+30.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dr Reddy's Laboratories Ltd (RDDA.SG)

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Dr. Reddy’s Q3 & 9MFY25 Financial Results

Dr. Reddy’s Laboratories Allocates Equity Shares to Employees

Dr. Reddy’s Boosts Workforce with Equity Allotment

Dr. Reddy’s Launches Innovative Cancer Drug in India

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy’s Gains Strong Rating Amid Robust Growth

Dr. Reddy’s Q2 & H1FY25 Financial Results

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Dr. Reddy’s Unveils New Danish Subsidiary

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Dr. Reddy’s Acquires Global NRT Leader Nicotinell

Dr. Reddy’s Expands Portfolio with $620M Investment

Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Performance Overview